button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mCRC - 2nd line (L2) metastatic/advanced - colorectal cancer (mCRC) mCRC - 2nd line (L2)

versus regorafenib
atezolizumab alone vs. regorafenib 1 certainty unassessable0% certainty unassessable+39%-
atezolizumab plus cometinib vs. regorafenib 1 certainty unassessable0% certainty unassessable+25%-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons